宫颈癌新辅助化疗耐药分子生物标志物的研究现状

Research advances of chemoresistance biomarkers of neoadjuvant chemotherapy for cervical cancer

新辅助化疗已经广泛用于各种癌症包括宫颈癌的治疗,同步放化疗是当前局部晚期宫颈癌患者的标准疗法,有效的新辅助化疗可以减小肿瘤体积、增加手术的可实施性,此外,新辅助化疗也可提高局部晚期宫颈癌患者的预后。但对顺铂为基础的化疗耐药仍然是临床治疗中的一个障碍,易发生肿瘤的复发。本综述从新辅助化疗顺铂耐药的角度出发,探讨新辅助化疗中与顺铂类化疗抵抗相关的分子生物学标志物研究现状。

Neoadjuvant chemotherapy(NAC)has been widely used in the treatment of various cancers,including cervicalcancer.Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer(LACC).Besides,effective NAC can reduce tumor size and facilitate hysterectomy for LACC.NAC treatment could improve the prognosis with LACC.But cisplatin-based chemotherapy resistance is still a barrier in cancer treatment and consequently leads to tumor relaps.This review explores the advances in molecular biomarkers associated with cisplatin-based chemoresistance in neoadjuvant chemotherapy for cervical cancer.